Evidence map›Paper›PMID 39633572›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2025

Human Genetic Evidence to Inform Clinical Development of IL-6 Signaling Inhibition for Abdominal Aortic Aneurysm.

Stephen Burgess, Héléne T Cronjé, Emil deGoma, Yung Chyung, Dipender Gill

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Aging-AssociatedJournal of the American Heart Association · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stephen BurgessMedical Research Council Biostatistics Unit (S.B., H.T.C.), University of Cambridge, United Kingdom.ORCID 0000-0001-5365-8760
Héléne T CronjéMedical Research Council Biostatistics Unit (S.B., H.T.C.), University of Cambridge, United Kingdom.
Emil deGomaTourmaline Bio, New York, NY (E.d., Y.C.).
Yung ChyungTourmaline Bio, New York, NY (E.d., Y.C.).
Dipender GillSequoia Genetics, London, United Kingdom (S.B., H.T.C., D.G.).ORCID 0000-0001-7312-7078

Funding

Wellcome Trust 225790
6 · The paper itself

Abstract

backgroundAbdominal aortic aneurysm (AAA) represents a significant cause of mortality, yet no medical therapies have proven efficacious. The aim of the current study was to leverage human genetic evidence to inform clinical development of IL-6 (interleukin-6) signaling inhibition for the treatment of AAA.

methodsAssociations of rs2228145, a missense variant in the

resultsWe observed strong genetic associations with AAA risk in the AAAgen consortium, UK Biobank, and FinnGen (odds ratios: 0.91 [95% CI, 0.90-0.92],

conclusionsInhibition of IL-6 signaling is a promising strategy for treating AAA but not other types of aneurysmal disease. These findings serve to help inform clinical development of IL-6 signaling inhibition for AAA treatment.

Indexed as

Aortic Aneurysm, AbdominalInterleukin-6Interleukin-6 InhibitorsReceptors, Interleukin-6AgedCase-Control StudiesCOVID-19FemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPolymorphism, Single NucleotideRisk AssessmentRisk FactorsSignal TransductionIL6 protein, humanIL6R protein, humanInterleukin-6Interleukin-6 InhibitorsReceptors, Interleukin-6aortic aneurysm, abdominalaortic aneurysm, thoracicarthritis, rheumatoidcollagen diseaseshuman genetics

Identifiers

PMID39633572
PMCPMC7617413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.